A bacteria-based immunotherapy product that has been used in the treatment of bladder cancer for the past 40 years is now in short supply, and it appears that the situation will continue for the rest ...
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has authorized an expanded access ...
ImmunityBio says Anktiva plus BCG showed durable survival and bladder preservation at 36 months in BCG-unresponsive bladder ...
The phase 3, open-label, single arm BOND-003 trial also evaluated cretostimogene in cohort P with papillary-only high-grade NMIBC who failed prior BCG therapy.
The worsening shortage of a bladder cancer drug solely manufactured by Merck has undoubtedly led to deaths, Pittsburgh urologist Ben Davies, MD, told CNBC. The shortage of Tice BCG, a biologic drug ...
Armed with new three-year data demonstrating the benefits of Anktiva in a specific patient subset, ImmunityBio is proving its ...
Supplies of BCG, a critical immunotherapy drug that treats bladder cancer, are dwindling, according to a STAT news report. The shortage of the medication is being felt across the nation, as hospitals ...
CG Oncology leads in NMIBC treatment with creto, strong efficacy data, and $2B+ revenue potential. Learn more about CGON ...
ANKTIVA plus BCG is the first immunotherapy for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback